Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 14/20 | 0.41 |
| ▸ | MET | P08581 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16863199 | 0.83 | AXL (0.54) | AXLMET | |
| SCHEMBL3484744 | 0.82 | EPHB3 (0.39) | DRD2DRD4DRD3CYP3A4TSHR | |
| SCHEMBL3484559 | 0.78 | KMT2A (0.56) | AXLCYP3A4MEN1KMT2A | |
| SCHEMBL16863242 | 0.78 | AXL (0.45) | AXLMETCYP3A4TSHRMEN1 | |
| SCHEMBL1968020 | 0.78 | AXL (0.48) | AXLMETMAP4K4 | |
| SCHEMBL1964539 | 0.74 | CYP3A4 (0.56) | CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL3484150 | 0.74 | DRD2 (0.38) | DRD2DRD4DRD3CYP3A4TSHR | |
| SCHEMBL3484131 | 0.74 | NUDT1 (0.37) | CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL632218 | 0.73 | CYP3A4 (0.46) | CYP3A4TSHRAR | |
| SCHEMBL3483796 | 0.72 | PDE7A (0.41) | DRD2DRD4DRD3CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | AXL 131/4885MET 24/4885DRD2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.